RNAZ Earnings Transcode Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–24 of 24
| Q2 2026 | 2026-06-30 | -28.14 | 2026-08-14 | 10-Q |
| Q1 2026 | 2026-03-31 | -21.28 | 2026-05-15 | 10-Q |
| FY 2025 | 2025-12-31 | -52.59 | 2026-04-15 | 10-K |
| Q3 2025 | 2025-09-30 | -34.49 | 2025-11-14 | 10-Q |
| Q2 2026 | 2025-06-30 | -32.45 | 2026-08-14 | 10-Q |
| Q1 2026 | 2025-03-31 | -70.16 | 2026-05-15 | 10-Q |
| FY 2025 | 2024-12-31 | -1336.63 | 2026-04-15 | 10-K |
| Q3 2025 | 2024-09-30 | -1117.89 | 2025-11-14 | 10-Q |
| Q2 2025 | 2024-06-30 | -1290.94 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -21.35 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -3419.01 | 2025-04-15 | 10-K |
| Q3 2024 | 2023-09-30 | -273.66 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -373.15 | 2024-08-14 | 10-Q |
| Q3 2023 | 2023-03-31 | -259.07 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | -1082.79 | 2024-04-01 | 10-K |
| Q3 2023 | 2022-09-30 | -19.16 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -12.55 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.27 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -0.81 | 2023-03-31 | 10-K |
| Q3 2022 | 2021-09-30 | -0.58 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.37 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.97 | 2022-05-16 | 10-Q |
| FY 2021 | 2020-12-31 | -0.51 | 2022-03-31 | 10-K |
| Q2 2021 | 2020-06-30 | -0.04 | 2021-08-23 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.